Table IV.
Survival analysis in multilpe myeloma patients without severe renal insufficiency by Cox proportional hazards model.
| Univariate
|
Multivariate
|
||||||
|---|---|---|---|---|---|---|---|
| n | HR | 95% CI | P-value | HR | 95% CI | P-value | |
| Age (years) | |||||||
| <65 | 14 | ||||||
| ≥65 | 17 | 1.76 | 0.60–5.16 | 0.31 | |||
| Hemoglobin (g/dl) | |||||||
| ≥10 | 18 | ||||||
| <10 | 13 | 2.01 | 0.72–5.60 | 0.18 | |||
| Platelet count (/μl) | |||||||
| ≥130,000 | 26 | ||||||
| <130,000 | 5 | 5.33 | 1.38–20.55 | 0.02 | |||
| LDH | |||||||
| normal | 27 | ||||||
| abnormal | 4 | 4.23 | 0.83–21.53 | 0.08 | |||
| ALP (IU/l) | |||||||
| ≤260 | 21 | ||||||
| >260 | 10 | 0.97 | 0.30–3.09 | 0.95 | |||
| Calcium (mg/dl) | |||||||
| <10 | 28 | ||||||
| ≥10 | 3 | 6.61 | 1.19–36.81 | 0.03 | 3.63 | 0.65–20.26 | 0.14 |
| Albumin (g/dl) | |||||||
| ≥3.5 | 27 | ||||||
| <3.5 | 4 | 1.87 | 0.50–6.94 | 0.35 | |||
| Bone marrow plasma cells (%) | |||||||
| <33 | 15 | ||||||
| ≥33 | 16 | 2.29 | 0.76–6.86 | 0.14 | |||
| Sβ2M (mg/l) | |||||||
| <3.5 | 18 | ||||||
| ≥3.5 | 13 | 2.98 | 1.02–8.74 | 0.046 | |||
| Performance status | |||||||
| 1–3 | 29 | ||||||
| 4 | 2 | 4.49 | 0.93–21.72 | 0.06 | |||
| Prohepcidin (ng/ml) | |||||||
| ≥110 | 16 | ||||||
| <110 | 15 | 6.24 | 1.82–21.35 | 0.004 | 5.65 | 1.60–19.95 | 0.01 |
| IL-6 (pg/ml) | |||||||
| <4 | 15 | ||||||
| ≥4 | 14 | 1.29 | 0.44–3.76 | 0.64 | |||
| TNF-α (pg/ml) | |||||||
| <15.6 | 18 | ||||||
| ≥15.6 | 10 | 0.78 | 0.26–2.30 | 0.65 | |||
| IL-1β (pg/ml) | |||||||
| <10 | 23 | ||||||
| ≥10 | 1 | 10.99 | 1.00–121.24 | 0.05 | |||
HR, hazard ratio; CI, confidence interval; LDH, lactate dehydrogenase; ALP, alkaline phosphatase; Sβ2M, serum β2-microglobulin; IL, interleukin; TNF, tumor necrosis factor.